Clinical trial NCT00352144: 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
Official title: A Six-Month, Chronic Efficacy and Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia: A Randomized Double-Blind, Placebo-Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Primary Insomnia
Lead sponsor: Sumitomo Pharma America, Inc.
Sponsor class: INDUSTRY
First posted: 2006-07-14
Enrollment: 830
Sex: ALL
Minimum age (years): 21
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the long-term efficacy of eszopiclone administered for up to 6 months in subjects with primary insomnia on subjective sleep measures, compared to placebo.

Detailed description: This is a double blind, randomized (2:1; eszopiclone : placebo), placebo-controlled, multicenter, study of eszopiclone in subjects with primary insomnia. The study will involve up to 9 visits and subject participation will be approximately 224 days. After meeting all screening criteria, subjects will be randomized to either eszopiclone 3 mg QD or placebo. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Eligibility criteria: Inclusion Criteria

* Subject meets DSM-IV criteria for primary insomnia and reports sleeping no more than 6.5 hours per night and/or taking more than 30 minutes each night to fall asleep for at least one month prior to screening.
* Male and female subjects must be between 21 and 64 years of age, inclusive, at the time of consent.
* Female subjects of childbearing potential must sign the Women of Childbearing Potential Addendum to the informed consent form. Females considered not of childbearing potential must be surgically sterile or greater than one-year post menopausal, defined as a complete cessation of menstruation for at least one year.
* Subject must be in general good health, based on screening physical examination (including brief neurological examination), medical history, 12-lead ECG, and clinical laboratory values (hematology, serum chemistry and urinalysis).

Exclusion Criteria

* Subject has any clinically significant unstable medical abnormality, chronic disease, or a history of a clinically significant abnormality of the cardiovascular, respiratory, hepatic, or renal systems.
* Subject has a history of cancer within the past 5 years, or current malignancy except for non melanomatous skin cancer.
* Subject has a psychiatric diagnosis with psychosis, dementia or delirium. Subjects with Sexual and Gender Identity Disorders or other non-psychotic disorders will be considered on a case-by-case basis.
* Subject has one of the following Personality Disorders: schizotypal, schizoid, or borderline personality disorder.
* Subject has difficulties in sleep initiation or maintenance associated with known medical diagnosis (e.g. sleep apnea, restless leg syndrome (RLS), or periodic leg movement syndrome (PLMS), or has any condition that has or may affect sleep (e.g., chronic pain, BPH, etc.).
* Subject has participated in a previous eszopiclone clinical trial.
* Subject has a known sensitivity to racemic zopiclone, any benzodiazepine, any sedative hypnotic, any substance that is contained in the formulation, or has been hospitalized for any allergic conditions (e.g. recurrent dermatitis, drug hypersensitivity, drug allergy, etc.).
* Subject has history of substance abuse in the past 10 years or substance dependence at any time or positive urine drug test at screening .
* Subject tests positive at screening for hepatitis B surface antigen, hepatitis C antibody or has a history of a positive result.
* Subject is known to be seropositive for HIV.
* Female subjects who are pregnant, lactating or within 6 months post partum.
* Subject self-reports consumption of more than two alcoholic beverages daily, 14 or more alcoholic beverages weekly, or five or more alcoholic beverages on any given day.
* Subject has taken any psychotropic medications or other medications known to affect sleep within the 3 days prior to screening visit or is anticipated to need any of these types of medications during double-blind treatment .
* Subject has participated in any investigational study within 30 days prior to screening.
* Subject has taken herbal supplements, purported to have central nervous system effects,(tablets, powders, extracts or tinctures) or combination products with herbs or melatonin within 14 days prior to screening or St. John's Wort within 30 days prior to screening.
* Subject is a rotating or third/night shift worker.
* Subject is a staff member or relative of a staff member.

Primary outcomes:
measure: Average of Subjective Sleep Latency
timeFrame: Days -14, 1, 30, 60, 90, 120, 150, 180
Secondary outcomes:
measure: Average of Total Sleep Time (TST) and Wake Time After Sleep Onset (WASO)
timeFrame: Days -14, 1, 30, 60, 90, 120, 150, 180
measure: SF-36
timeFrame: Days 1, 30, 90, 180
measure: Work Limitations Questionnaire (WLQ)
timeFrame: Days 1, 30, 90, 180
measure: Insomnia Severity Index (ISI)
timeFrame: Days 1, 30, 90, 180
measure: Fatigue Severity Scale (FSS)
timeFrame: Days 1, 30, 90, 180
measure: Epworth Sleepiness Scale (ESS)
timeFrame: Days 1, 30, 60, 90, 120, 150, 180
measure: Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ)
timeFrame: Day 180
measure: Healthcare Utilization Questionnaire (HUQ)
timeFrame: Days 1, 30, 60, 90, 120, 150, 180
Other outcomes:
Locations:
city: Birmingham
country: United States
state: Alabama
city: Huntsville
country: United States
state: Alabama
city: Phoenix
country: United States
state: Arizona
city: Scottsdale
country: United States
state: Arizona
city: Anaheim
country: United States
state: California
city: Irvine
country: United States
state: California
city: Oakland
country: United States
state: California
city: Redlands
country: United States
state: California
city: San Diego
country: United States
state: California
city: Aurora
country: United States
state: Colorado
city: Denver
country: United States
state: Colorado
city: Longmont
country: United States
state: Colorado
city: Pueblo
country: United States
state: Colorado
city: Clearwater
country: United States
state: Florida
city: Jacksonville
country: United States
state: Florida
city: Jupiter
country: United States
state: Florida
city: Naples
country: United States
state: Florida
city: Orlando
country: United States
state: Florida
city: Pembroke Pines
country: United States
state: Florida
city: Pinellas Park
country: United States
state: Florida
city: St. Petersburg
country: United States
state: Florida
city: Tampa
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Blairsville
country: United States
state: Georgia
city: Chicago
country: United States
state: Illinois
city: Elk Grove Village
country: United States
state: Illinois
city: Northbrook
country: United States
state: Illinois
city: Evansville
country: United States
state: Indiana
city: Olathe
country: United States
state: Kansas
city: Prairie Village
country: United States
state: Kansas
city: Chevy Chase
country: United States
state: Maryland
city: Frederick
country: United States
state: Maryland
city: Newton
country: United States
state: Massachusetts
city: Kansas City
country: United States
state: Missouri
city: St. Louis
country: United States
state: Missouri
city: Lincoln
country: United States
state: Nebraska
city: Las Vegas
country: United States
state: Nevada
city: Hamilton
country: United States
state: New Jersey
city: New York
country: United States
state: New York
city: Cary
country: United States
state: North Carolina
city: Cincinatti
country: United States
state: Ohio
city: Cleveland
country: United States
state: Ohio
city: Columbus
country: United States
state: Ohio
city: Mogadore
country: United States
state: Ohio
city: Oklahoma City
country: United States
state: Oklahoma
city: Eugene
country: United States
state: Oregon
city: Bala Cynwyd
country: United States
state: Pennsylvania
city: Anderson
country: United States
state: South Carolina
city: Columbia
country: United States
state: South Carolina
city: Austin
country: United States
state: Texas
city: Dallas
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Jackson
country: United States
state: Texas
city: Lubbock
country: United States
state: Texas
city: Plano
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Brown Deer
country: United States
state: Wisconsin
city: Madison
country: United States
state: Wisconsin
Study officials:
References: